Blow to biosimilars in amended US health care act
16 July 2009
Eileen McDermott, New York
A US Senate committee adopted an amendment to health care legislation on Monday night that will give 12 years of data exclusivity to innovative biologics
The amendment – adopted by the Senate Health, Education, Labor and Pensions (HELP) Committee and sponsored by Senators Orrin Hatch, Kay Hagan and Mike Enzi - represents an important win for the biotechnology industry.
The Obama administration, the Federal Trade Commission (FTC) and groups including the America Association of Retired Persons (AARP) all have proposed much shorter periods of protection before allowing biosimilar products on the market.
A biosimilar, or follow-on biologic, is a product that attempts to replicate a biologic – a...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial